ArticleMolecules (Basel, Switzerland)2022
Novasomes as Nano-Vesicular Carriers to Enhance Topical Delivery of Fluconazole: A New Approach to Treat Fungal Infections.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Vismodegib-loaded ufasomes inhaler for treatment of non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Design and optimization of isoxsuprine-loaded novasomes for the attenuation of coronary artery disease in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Resveratrol-loaded novasomal gel for sustained dermal delivery against monobenzone-induced vitiligo-like depigmentation in black chicks.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Management of diabetes mellitus-associated atherosclerosis via simvastatin-loaded novasomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Novasomal Gel for Enhanced Dermal Delivery and Antibacterial Efficacy of Cinnamic Acid.Molecules (Basel, Switzerland) · 2026Article
- Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer.International journal of pharmaceutics: X · 2026Article
- Preparation and evaluation of citalopram novasomal vesicles as a transdermal analgesic drug delivery.Drug delivery and translational research · 2026Article
- Optimizing Transdermal Drug Delivery with Novasome Nanocarriers: A Quality by Design (QbD) Framework.Current drug delivery · 2026Review
- Formulation and Characterization of Oxiconazole-Loaded Novasomes to Enhance the Treatment of Fungus Infections: Experimentally Induced Candidiasis in Rat.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Development and Evaluation of Nystatin-Loaded Novasomal Gel for the Treatment ofGels (Basel, Switzerland) · 2025Article
- Nasal In-Situ Gels of BrijAAPS PharmSciTech · 2025Article
- Fluconazole-loaded Hyaluronic Acid-modified Transfersomal Hydrogels Containing D-panthenol for Ocular Delivery in Fungal Keratitis Management.Current drug delivery · 2025Article
- The progress and future of the treatment of Candida albicans infections based on nanotechnology.Journal of nanobiotechnology · 2024Review
- Nanotechnology-based Drug Delivery of Topical Antifungal Agents.Pharmaceutical nanotechnology · 2024Review
- Thyme Oil-Containing Fluconazole-Loaded Transferosomal Bigel for Transdermal Delivery.AAPS PharmSciTech · 2023Article
- Development and Pharmacokinetic Evaluation of Novasomes for the Trans-nasal Delivery of Fluvoxamine Using Arachidonic Acid-Carboxymethyl Chitosan Conjugate.Pharmaceutics · 2023Article
- Recent Advances of Chitosan Formulations in Biomedical Applications.International journal of molecular sciences · 2022Review
- Alginate as a Promising Biopolymer in Drug Delivery and Wound Healing: A Review of the State-of-the-Art.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of fungal infections has increased over the past two decades. It is observed that superficial fungal infections are treated by conventional dosage forms, which are incapable of treating deep infections due to the barrier activity possessed by the stratum corneum of the skin. This is why the need for a topical preparation with advanced penetration techniques has arisen. This research aimed to encapsulate fluconazole (FLZ) in a novasome in order to improve the topical delivery. The novasomes were prepared using the ethanol injection technique and characterized for percent entrapment efficiency (EE), particle size (PS), zeta potential (ZP), drug release, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), scanning electron microscopy (SEM) and antifungal activity. The FN7 formulation with 94.45% EE, 110 nm PS and -24 ZP proved to be the best formulation. The FN7 formulation showed a 96% release of FLZ in 8 h. FTIR showed the compatibility of FLZ with excipients and DSC studies confirmed the thermal stability of FLZ in the developed formulation. The FN7 formulation showed superior inhibition of the growth of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.